Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Interest Expense : ¥-9 Mil (TTM As of Sep. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Hunan Er-Kang Pharmaceutical Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Hunan Er-Kang Pharmaceutical Co's interest expense for the three months ended in Sep. 2024 was ¥ -2 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was ¥-9 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Hunan Er-Kang Pharmaceutical Co's Operating Income for the three months ended in Sep. 2024 was ¥ -30 Mil. Hunan Er-Kang Pharmaceutical Co's Interest Expense for the three months ended in Sep. 2024 was ¥ -2 Mil. Hunan Er-Kang Pharmaceutical Co did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Hunan Er-Kang Pharmaceutical Co Interest Expense Historical Data

The historical data trend for Hunan Er-Kang Pharmaceutical Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hunan Er-Kang Pharmaceutical Co Interest Expense Chart

Hunan Er-Kang Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-2.98

-12.16

-9.29

-5.50

-6.66

Hunan Er-Kang Pharmaceutical Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Expense	Get a 7-Day Free Trial															-0.96	-1.14	-3.76	-2.50	-2.00

Hunan Er-Kang Pharmaceutical Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-9 Mil.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Hunan Er-Kang Pharmaceutical Co's Interest Expense for the three months ended in Sep. 2024 was ¥-2 Mil. Its Operating Income for the three months ended in Sep. 2024 was ¥-30 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was ¥6 Mil.

Hunan Er-Kang Pharmaceutical Co's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

Hunan Er-Kang Pharmaceutical Co did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Hunan Er-Kang Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Er-Kang Pharmaceutical Co Ltd (SZSE:300267) » Definitions » Interest Expense

Traded in Other Exchanges

N/A

Address

Kangping Road 167, National Economic and Technological Development Zone, Liuyang Changsha, Hunan, CHN, 410331

Website

http://www.hnerkang.com

Hunan Er-Kang Pharmaceutical Co Ltd develops, produces and sells pharmaceutical products in China. The company's main products include pharmaceutical excipients and antibiotics. It offers pharmaceutical excipients, APIs and finished drug products. The pharmaceutical excipients include products such as glycerol, ethanol pharmaceutically, acceptable propylene glycol, sodium hydroxide, and pharmaceutically acceptable sugar. The company's finished drugs primarily include sulbenicillin sodium for injection and compound liquorice tablets. Its APIs include glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. Geographically, all the activities are carried out through China.

Executives

Shuai Fang Wen	Director
Wang Jun Wen	Independent director
Zuo Tian Fang	Independent director
Qi Yang	Supervisors
Li Yi Guo	Supervisors
Chen Wen Xian	Supervisors
Wang Xiang Feng	Directors, executives
Liu Ai Jun	Directors, executives
Luo Lang	Directors, executives
Fan Yi	Securities Affairs Representative
Yang Hai Ming	Directors, executives
Shuai You Wen	Director
Shuai Rui Wen	Director
Gao Zhen Ya	Executives
Cao Zai Yun	Director

Hunan Er-Kang Pharmaceutical Co Headlines

No Headlines